Bausch Health Companies Inc
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We own and lease a number of properties. Our headquarters and one of our manufacturing facilities are located in Laval, Quebec. We own several manufacturing facilities throughout the U.S. We also own or have an interest in manufacturing plants or other properties outside the U.S., including in Canada, Mexico, and certain countries in Europe, Asia and South America.
We consider our facilities to be in satisfactory condition and suitable for their intended use. Our administrative, marketing, research/laboratory, distribution and warehousing facilities are located in various parts of the world. We co-locate our R&D activities with our manufacturing at the plant level in a number of facilities. Our scientists, engineers, quality assurance/quality control professionals and manufacturing technicians work side-by-side in designing and manufacturing products that fit the needs and requirements of our customers, regulators and business units.
We believe that we have sufficient facilities to conduct our operations. Our facilities in aggregate are approximately 10 million square feet and include, among others, the following principal properties:
| Bausch Health Location | Purpose | OwnedorLeased | ApproximateSquareFootage |
|---|---|---|---|
| Laval, Quebec, Canada | Corporate headquarters, R&D, manufacturing and warehouse facility | Owned | 338,000 |
| Bridgewater, New Jersey(1) | Administration shared with Bausch + Lomb | Leased | 310,000 |
| San Juan del Rio, Mexico | Offices and manufacturing facility | Owned | 853,000 |
| Jelenia Gora, Poland | Offices, R&D, manufacturing and warehouse facility | Owned | 521,000 |
| Rzeszow, Poland | Offices, R&D, manufacturing and warehouse facility | Owned | 380,000 |
| Steinbach, Canada | Offices, manufacturing and warehouse facility | Owned | 241,000 |
| Bausch + Lomb Location | Purpose | OwnedorLeased | ApproximateSquareFootage |
| Vaughan, Ontario, Canada | Corporate headquarters and distribution facility | Leased | 66,000 |
| Bridgewater, New Jersey | Administration shared with Bausch Health | Leased | 310,000 |
| Rochester, New York | Offices, R&D and manufacturing facility | Owned | 953,000 |
| Waterford, Ireland | R&D and manufacturing facility | Owned | 500,000 |
| Woodruff, South Carolina | Distribution facility | Leased | 432,000 |
| Jinan, China | Offices and manufacturing facility | Owned | 418,000 |
| Berlin, Germany | R&D, manufacturing, distribution and office facility | Owned | 339,000 |
| Greenville, South Carolina | Manufacturing facility | Owned | 314,000 |
| Lynchburg, Virginia | Offices and distribution facility | Owned | 224,000 |
| Aubenas, France | Offices, manufacturing and warehouse facility | Owned | 193,000 |
| Tampa, Florida | R&D and manufacturing facility | Owned | 171,000 |
| St. Louis, Missouri | Offices, R&D and manufacturing facility | Owned | 140,000 |
| Macherio, Italy | Offices, manufacturing and warehouse facility | Owned | 119,000 |
| Clearwater, Florida | R&D and manufacturing facility | Owned | 102,000 |
| Beijing, China | Manufacturing facility | Owned | 97,000 |
(1) — A lease for a second building in Bridgewater, New Jersey was signed in 2015 and was not included in the square footage shown in the table above as the Company has never occupied the second building. In 2016, the Company concluded that it would not occupy the second building and recognized the appropriate charge for all future rents due, net of the anticipated sub-let income associated with the second building. In 2023, the Company decided to exercise an option to early terminate the lease period. As a result, the Company recognized an impairment to the right-of-use asset and a charge for the required termination payment.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.